SELLAS Life Sciences Group Operating Expenses Growth & History (SLS)
SELLAS Life Sciences Group's operating expenses was $28.3M for fiscal 2025.
View full SELLAS Life Sciences Group company overviewSELLAS Life Sciences Group annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.3M | −$3.2M | −10.28% |
| 2024 | 2024-12-31 | $31.5M | −$6.4M | −16.78% |
| 2023 | 2023-12-31 | $37.9M | −$5.1M | −11.83% |
| 2022 | 2022-12-31 | $43.0M | $10.1M | +30.57% |
| 2021 | 2021-12-31 | $32.9M | $14.0M | +74.21% |
| 2020 | 2020-12-31 | $18.9M | −$1.2M | −5.78% |
| 2019 | 2019-12-31 | $20.0M | — | — |
| 2016 | 2016-12-31 | $31.9M | −$2.4M | −6.88% |
| 2015 | 2015-12-31 | $34.2M | −$9.7M | −22.05% |
| 2014 | 2014-12-31 | $43.9M | $15.4M | +54.09% |
| 2013 | 2013-12-31 | $28.5M | $7.3M | +34.39% |
| 2012 | 2012-12-31 | $21.2M | $8.7M | +69.78% |
| 2011 | 2011-12-31 | $12.5M | −$4.1M | −24.90% |
| 2010 | 2010-12-31 | $16.6M | — | — |
SELLAS Life Sciences Group quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.6M | $3.8M | +54.65% |
| Q1 2026 | 2026-03-31 | $9.3M | $3.2M | +52.60% |
| Q4 2025 | 2025-12-31 | $8.3M | — | — |
| Q3 2025 | 2025-09-30 | $7.1M | — | — |
| Q2 2025 | 2025-06-30 | $6.9M | — | — |
| Q1 2025 | 2025-03-31 | $6.1M | — | — |
| Q4 2023 | 2023-12-31 | $8.2M | −$1.3M | −13.43% |
| Q3 2023 | 2023-09-30 | $9.4M | $2.2M | +31.00% |
| Q2 2023 | 2023-06-30 | $9.1M | $427,000 | +4.95% |
| Q1 2023 | 2023-03-31 | $11.3M | −$6.5M | −36.39% |
| Q4 2022 | 2022-12-31 | $9.4M | −$2.2M | −18.70% |
| Q3 2022 | 2022-09-30 | $7.1M | $169,000 | +2.42% |
| Q2 2022 | 2022-06-30 | $8.6M | $2.3M | +35.73% |
| Q1 2022 | 2022-03-31 | $17.7M | $9.8M | +123.22% |
| Q4 2021 | 2021-12-31 | $11.6M | $5.6M | +91.76% |
| Q3 2021 | 2021-09-30 | $7.0M | $2.5M | +55.32% |
| Q2 2021 | 2021-06-30 | $6.4M | $2.1M | +48.89% |
| Q1 2021 | 2021-03-31 | $7.9M | $3.9M | +95.50% |
| Q4 2020 | 2020-12-31 | $6.1M | — | — |
| Q3 2020 | 2020-09-30 | $4.5M | — | — |
| Q2 2020 | 2020-06-30 | $4.3M | — | — |
| Q1 2020 | 2020-03-31 | $4.1M | — | — |
| Q2 2015 | 2015-06-30 | $12.0M | −$6.1M | −33.77% |
| Q1 2015 | 2015-03-31 | $11.3M | −$2.8M | −19.63% |
| Q4 2014 | 2014-12-31 | $8.4M | $2.3M | +37.32% |
| Q3 2014 | 2014-09-30 | $11.9M | $4.2M | +53.83% |
| Q2 2014 | 2014-06-30 | $18.1M | $10.1M | +126.82% |
| Q1 2014 | 2014-03-31 | $14.0M | $7.4M | +112.10% |
| Q4 2013 | 2013-12-31 | $6.1M | $552,000 | +9.90% |
| Q3 2013 | 2013-09-30 | $7.8M | $2.2M | +40.41% |
| Q2 2013 | 2013-06-30 | $8.0M | $2.3M | +40.52% |
| Q1 2013 | 2013-03-31 | $6.6M | $2.2M | +49.91% |
| Q4 2012 | 2012-12-31 | $5.6M | $4.1M | +272.36% |
| Q3 2012 | 2012-09-30 | $5.5M | $2.1M | +60.93% |
| Q2 2012 | 2012-06-30 | $5.7M | $3.4M | +149.47% |
| Q1 2012 | 2012-03-31 | $4.4M | −$865,000 | −16.40% |
| Q4 2011 | 2011-12-31 | $1.5M | — | — |
| Q3 2011 | 2011-09-30 | $3.4M | −$284,000 | −7.64% |
| Q2 2011 | 2011-06-30 | $2.3M | −$2.5M | −52.08% |
| Q1 2011 | 2011-03-31 | $5.3M | — | — |
| Q3 2010 | 2010-09-30 | $3.7M | — | — |
| Q2 2010 | 2010-06-30 | $4.8M | — | — |
SELLAS Life Sciences Group operating expenses trends
Over the last five fiscal years, SELLAS Life Sciences Group's operating expenses increased from $18.9M to $28.3M, a change of $9.4M. The latest reported quarter, Q2 2026, shows $10.6M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SELLAS Life Sciences Group source filings ↗